PURE BIOSCIENCE, INC.

PURE BIOSCIENCE, INC. Annual Report Summary - 2023 Performance

Here’s what everyday investors need to know about Pure Bioscience’s year, stripped down to the essentials:

---

1. What They Do

Pure Bioscience makes SDC, a silver-based disinfectant that’s safer than bleach or harsh chemicals. Their target markets: hospitals, farms, and food production facilities.

2023 Vibe: Mixed progress. They gained new clients but faced slower-than-expected growth.

---

2. Financial Snapshot

• Revenue: $1.2 million (down 20% from $1.5M in 2022)
• Net Loss: $4.8 million (worse than 2022’s $4.3M loss)
• Cash Left: $1.9 million (down from $3.6M last year)

Translation: Sales dropped, losses grew, and cash reserves are shrinking.

---

3. Wins vs. Challenges

✅ Wins:

• Landed contracts with a national food processor and a hospital chain.
• EPA approved SDC for mold remediation (new revenue opportunity!).

❌ Challenges:

• Supply chain delays hurt product availability.
• Big competitors slashed prices, making it harder to compete.

---

4. Financial Health Check

• Cash Runway: Only 6-9 months left at current spending rates.
• Debt: Minimal (good!), but they’ll likely need to raise more money soon (could dilute shares).
• Audit Costs: $136K (down slightly from 2022).

Bottom Line: Survival hinges on sales growth or new funding. Risky, but not hopeless.

---

5. Leadership & Strategy Shifts

• New CEO in 2023 shifted focus to partnerships (instead of direct sales) and prioritized food safety/healthcare markets.
• The company didn’t provide much detail about long-term R&D plans.

---

6. Risks to Know

• Cash Crunch: Running out of money within a year could tank the stock.
• Slow Adoption: Industries are slow to switch disinfectants.
• Competition: Giants like Clorox and Ecolab have deeper pockets.

---

7. Why They Might Still Win

• Green Trend: Demand for eco-friendly cleaners is rising—SDC fits perfectly.
• Niche Advantage: Their product works where traditional chemicals can’t (e.g., food processing).

---

8. 2024 Goals

• Boost sales in food safety and healthcare.
• Reduce costs.
• Secure new funding or partnerships.

---

Key Investor Takeaways

• High Risk, High Reward: Pure Bioscience has innovative tech but shaky finances.
• Speculative Play: Only consider if you’re comfortable with volatility.
• Make-or-Break Year: Success depends on executing their 2024 strategy flawlessly.

Final Note: The company shared limited details about future plans beyond 2024, which adds uncertainty. If you invest, watch for news about partnerships or funding—it’ll be critical to their survival.

---

This summary focuses on what matters most: annual performance, risks, and clear takeaways. Always do your own research before investing. 🚀